Prime editing enters the human body — what it means for medicine

First dose, first era

Prime Medicine has administered the first prime editing treatment directly inside a human body. The patient has Wilson disease, a rare genetic disorder caused by mutations in the ATP7B gene that prevent the liver from clearing excess copper. A viral vector carrying the prime editor was injected into the liver, where it rewrote the faulty DNA sequence in living cells. Results are expected next year.

The milestone matters because it marks the first time prime editing has ever been used in vivo. Until now, the technique has only been tested ex vivo — extracting cells, editing them in a lab, and reinjecting them. Getting prime editors to work inside the body is a harder problem. It requires delivering a larger molecular machine across cell membranes, reaching enough target cells, and avoiding immune reactions — all without off-target edits that could cause new damage.

Nature publishing the announcement is itself a signal. This is not a press-release claim; it is peer-recognized validation of a technique that has spent years in research labs and only recently entered clinical work.

Why Wilson disease was the right choice

Wilson disease is an unusual candidate for a first-in-human in-vivo prime edit, and that is deliberate. The liver is a large organ with considerable regenerative capacity, making it a practical delivery target. The disease is caused by mutations in a single gene, ATP7B, and the most common variants involve small, well-characterized changes that prime editing is designed to correct precisely.

Unlike base editing, which can swap individual DNA letters but cannot insert or delete larger sequences, prime editing can rewrite segments of DNA. That makes it one of the few techniques capable of fixing the mutations responsible for Wilson disease rather than simply disabling the broken gene.

Current treatments for Wilson disease rely on copper-chelating drugs and zinc salts taken for life. They manage the condition but do not cure it. A single in-vivo edit, if it works and endures, could replace years of medication with one procedure. That is what makes patients like Rhonda Rowland, president of the Wilson Disease Association, so eager for results.

The harder question: who gets this?

The more interesting story is not Wilson disease itself but what this trial proves about in-vivo gene editing. Manufacturing a bespoke ex-vivo therapy is slow and expensive — often costing hundreds of thousands of dollars per patient and requiring specialized facilities. An in-vivo treatment, delivered by injection, could be far cheaper and faster to produce. That changes the economics of rare-disease treatment in ways that affect insurers, regulators, and health systems worldwide.

But in-vivo editing also carries different risks. Off-target edits, immune responses to the viral vector or the editing enzyme, and long-term uncertainty about engineered DNA in living cells are all real concerns. Krishanu Saha, a biomedical engineer at the University of Wisconsin-Madison, put it bluntly: the approach depends on what types of risks you are willing to accept. The trade-off is clearer when you contrast ex-vivo and in-vivo. Ex-vivo therapies allow extensive quality control before cells enter the patient. In-vivo editing gives up that control for convenience and scale.

What comes next for regulation

No gene-editing therapy has yet been approved for in-vivo use in any major market. The FDA is expected to decide early next year on an in-vivo CRISPR-Cas9 therapy for hereditary angioedema, a condition causing severe swelling. That decision will set the first regulatory precedent for direct genome editing inside the body.

Prime Medicine’s Wilson disease trial runs in parallel. If the two programs both advance, regulators will face a new category of medicine: programmable in-vivo editors that rewrite DNA directly in organs. Existing frameworks for gene therapy and biologic drugs were not designed for this. Expect questions about what constitutes an adequate safety signal, how long patients need to be followed for delayed off-target effects, and whether a single corrected gene in the liver is sufficient proof of benefit or whether broader mechanistic data will be required.

The European Medicines Agency and other regulators outside the US will watch closely. Whatever precedent the FDA sets on in-vivo prime editing will ripple through global drug approval pathways. Companies developing similar therapies in China, Japan, and Europe will align their clinical programs to whichever standard emerges first.

Who wins and who loses

Prime Medicine wins credibility. Delivering the first in-vivo prime edit positions the company as a leader in a field that could encompass dozens of upcoming trials. Its earlier ex-vivo work on a rare immune disorder adds context — the same technology, different delivery route. If the Wilson disease results are positive, Prime Medicine’s pipeline valuation rises not just on one drug but on a platform that could treat many more.

Patients with Wilson disease and similar monogenic liver disorders win prospectively. They gain access to a potential cure that does not require cell extraction and manufacturing. Those with diseases that currently have no approved gene therapy at all may see new doors open if in-vivo editing proves safe in the liver.

Traditional gene therapy manufacturers may lose ground. Ex-vivo cell therapies have dominated the approved landscape, including Casgevy, the only gene-edited drug currently on the market. In-vivo approaches bypass much of the complex cell-culture infrastructure that defines that business. Companies built around bespoke ex-vivo manufacturing face a future in which a single injection could replace a months-long production run.

Regulators win accountability pressure. Every high-profile in-vivo edit forces stricter scrutiny. That is not negative — it is necessary. But it also means slower timelines and heavier data requirements for companies pursuing the same route.

What to watch

The first data readout from the Wilson disease trial is the next inflection point. Expect a Nature or New England Journal of Medicine paper alongside it. The FDA decision on the hereditary angioedema CRISPR therapy will arrive around the same time. Together, those two events will define the regulatory environment for in-vivo genome editing for years.

Prime Medicine has not disclosed the exact dose or viral vector used, nor the editing efficiency achieved in the first patient. That information will come with the full data release. Until then, the milestone itself — a prime editor working inside a human body — is the story.

The era of programmable medicine is no longer theoretical. It is in the clinic.